[Cancer immunotherapy: immunologic bases, reality and hopes]
Related Experiment Video
Updated: Nov 9, 2026

Co-Culture In Vitro Systems to Reproduce the Cancer-Immunity Cycle
Published on: June 7, 2024
P Y Dietrich1, F Farace, A Caignard
1Unité d'immunothérapie, Institut Gustave-Roussy, Villejuif, France.
Abstract:
The use of the immune system for the treatment of cancer is still debated. Recent advances in antigen presentation and recognition mechanisms, and the characterization of tumor-specific antigens generating a T cell response are crucial steps for the stimulation of research in this direction. These advances should allow the development of selective immunotherapy, either passive (infusion of lymphocytes with specific recognition of autologous tumor) or active (vaccination), and the evaluation of this new approach in cancer treatment strategies.
Related Concept Videos
Tumor Immunotherapy
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
